A case-control study of HIV seroconversion in health care workers after percutaneous exposure

被引:783
作者
Cardo, DM
Culver, DH
Ciesielski, CA
Srivastava, PU
Marcus, R
Abiteboul, D
Heptonstall, J
Ippolito, G
Lot, F
McKibben, P
Bell, DM
机构
[1] CTR DIS CONTROL,NATL CTR HIV STD & TB PREVENT,DIV HIV AIDS,ATLANTA,GA 30333
[2] INST NATL RECH & SECUR,PARIS,FRANCE
[3] GRP ETUD RISQUE EXPOSIT SANG,PARIS,FRANCE
[4] PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND
[5] CTR RIFERIMENTO AIDS COORDINAMENTO STUDIO ITALIAN,ROME,ITALY
[6] RESEAU NATL SANTE PUBL,ST MAURICE,FRANCE
关键词
D O I
10.1056/NEJM199711203372101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The average risk of human immunodeficiency virus (HIV) infection after percutaneous exposure to HIV-infected blood is 0.3 percent, but the factors that influence this risk are not well understood. Methods We conducted a case-control study Of health care workers with occupational, percutaneous exposure to HIV-infected blood. The case patients were those who became seropositive after exposure to HIV, as reported by national surveillance systems in France, Italy, the United Kingdom, and the United States. The controls were health care workers in a prospective surveillance project who were exposed to HIV but did not seroconvert. Results Logistic-regression analysis based on 33 case patients and 665 controls showed that significant risk factors for seroconversion were deep injury (odds ratio=15; 95 percent confidence interval, 6.0 to 41), injury with a device that was visibly contaminated with the source patient's blood (odds ratio=6.2; 95 percent confidence interval, 2.2 to 21), a procedure involving a needle placed in the source patient's artery or vein (odds ratio=4.3; 95 percent confidence interval, 1.7 to 12), and exposure to a source patient who died of the acquired immunodeficiency syndrome within two months afterward (odds ratio=5.6; 95 percent confidence interval, 2.0 to 16). The case patients were significantly less likely than the controls to have taken zidovudine after the exposure (odds ratio=0.19; 95 percent confidence interval, 0.06 to 0.52). Conclusions The risk of HIV infection after percutaneous exposure increases with a larger volume of blood and, probably, a higher titer of HIV in the source patient's blood. Postexposure prophylaxis with zidovudine appears to be protective. (C) 1997, Massachusetts Medical Society.
引用
收藏
页码:1485 / 1490
页数:6
相关论文
共 27 条
  • [1] BELL DM, 1992, INFECT AGENT DIS, V1, P263
  • [2] BELL DM, 1997, AM J MED 5B, V102
  • [3] BLACK R, 1997, AM J MED, V102
  • [4] Antiretroviral therapy for HIV infection in 1996 - Recommendations of an international panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02): : 146 - 154
  • [5] CHAMBERLAND ME, IN PRESS HOSP INFECT
  • [6] REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT
    CONNOR, EM
    SPERLING, RS
    GELBER, R
    KISELEV, P
    SCOTT, G
    OSULLIVAN, MJ
    VANDYKE, R
    BEY, M
    SHEARER, W
    JACOBSON, RL
    JIMENEZ, E
    ONEILL, E
    BAZIN, B
    DELFRAISSY, JF
    CULNANE, M
    COOMBS, R
    ELKINS, M
    MOYE, J
    STRATTON, P
    BALSLEY, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) : 1173 - 1180
  • [8] GERBERDING JL, 1997, AM J MED 5B, V102
  • [9] RISK FOR OCCUPATIONAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) ASSOCIATED WITH CLINICAL-EXPOSURES - A PROSPECTIVE EVALUATION
    HENDERSON, DK
    FAHEY, BJ
    WILLY, M
    SCHMITT, JM
    CAREY, K
    KOZIOL, DE
    LANE, HC
    FEDIO, J
    SAAH, AJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 113 (10) : 740 - 746
  • [10] QUANTITATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 IN THE BLOOD OF INFECTED PERSONS
    HO, DD
    MOUDGIL, T
    ALAM, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) : 1621 - 1625